Drug Profile
Neuropathic pain therapeutic - Boehringer Ingelheim
Latest Information Update: 25 Sep 2019
Price :
$50
*
At a glance
- Originator Boehringer Ingelheim; Evotec AG
- Developer Boehringer Ingelheim
- Class Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Neuropathic pain
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for phase-I development in Neuropathic-pain in Germany
- 31 May 2011 Boehringer Ingelheim and Evotec initiate a phase I trial of its back-up neuropathic pain therapeutic in Germany
- 20 May 2010 Phase-I clinical trials in Neuropathic pain in Germany (unspecified route)